Skip to content

US · TLSI · MEDICAL - DEVICES

TriSalus Life Sciences, Inc. (TLSI) intrinsic value and stock valuation

$2.32as of 2026-11-21 · Mkt cap 212.68M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

TriSalus Life Sciences, Inc. DCF and intrinsic value

InvestorsCraft values TLSI with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from TLSI’s statements →

TriSalus Life Sciences, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Westminster, CO 80031 trisaluslifesci.com

How the business is doing

Fiscal 2020–2025, USD

Revenue
$45.2M
20202025
Net income
-$-39.23M
20202025
Free cash flow
-$-18.93M
20202025
Total equity
-$-33.86M
20202025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2020–2025, USD
20252024202320222021
Revenue$45.2M$29.4M$18.5M$12.4M$8.4M
Operating income-$-26.95M-$-36.16M-$-54.48M-$-36.44M-$-24.03M
Net income-$-39.23M-$-33.23M-$-59.36M-$-47.19M-$-28.84M
EPSd-$-1.04M-$-1.25M-$-2.24M-$-1.59M-$-922.88K
Operating cash flow-$-18.01M-$-40.84M-$-50.58M-$-32.31M-$-22.7M
Capital expenditure-$-920K-$-340K-$-590K-$-790K-$-1.26M
Free cash flow-$-18.93M-$-41.19M-$-51.17M-$-33.1M-$-23.95M
Total assets$35.3M$24M$24.6M$22M$37.8M
Total debt$34.4M$23.6M$1.59M$1.96M$0.00
Net debt$14M$15.1M-$-10.18M-$-7.45M-$-30.3M
Total equity-$-33.86M-$-25.89M-$-27.07M-$-12.32M$30.9M
Cash and short-term investments$20.4M$8.53M$11.8M$9.41M$30.3M
Income statement
20252024202320222021
Revenue$45.2M$29.4M$18.5M$12.4M$8.4M
Cost of revenue$6.96M$4.1M$2.6M$2.26M$1.19M
Gross profit$38.2M$25.3M$15.9M$10.1M$7.21M
Research and development expenses$15M$17.7M$29.8M$21.4M$14.2M
Selling, general and administrative expenses$50.2M$43.8M$40.6M$25.2M$17M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$65.1M$61.5M$70.4M$46.6M$31.2M
Cost and expenses$72.1M$65.6M$73M$48.8M$32.4M
Interest income$560K$400K$430K$180K$0.00
Interest expense$5.54M$3.09M$20K$0.00$1.76M
Depreciation and amortization$630K$740K$680K$410K$460K
Ebitda-$-33.05M-$-32.38M-$-58.65M-$-46.76M-$-26.62M
Operating income-$-26.95M-$-36.16M-$-54.48M-$-36.44M-$-24.03M
Total other income/expenses, net-$-12.27M$6.13M-$-4.88M-$-10.74M-$-4.81M
Income before tax-$-39.22M-$-30.04M-$-59.35M-$-47.18M-$-28.84M
Income tax expense$10K$10K$10K$10K$0.00
Net income-$-39.23M-$-33.23M-$-59.36M-$-47.19M-$-28.84M
Weighted average shares outstanding$49.2M$26.5M$26.5M$29.6M$31.3M
Weighted average diluted shares outstanding$37.9M$26.5M$26.5M$29.6M$31.3M
Balance sheet
20252024202320222021
Cash and short-term investments$20.4M$8.53M$11.8M$9.41M$30.3M
Net receivables$6.56M$5.09M$3.55M$1.56M$1.36M
Inventory$3.08M$4.05M$2.54M$1.47M$1.29M
Total current assets$32.2M$20.7M$20.9M$17.2M$35.1M
Property, plant and equipment, net$2.67M$2.88M$3.27M$3.61M$1.8M
Goodwill and intangible assets$0.00$0.00$0.00$800K$790K
Long-term investments$400K$350K$0.00$250K$0.00
Total non-current assets$3.09M$3.3M$3.74M$4.78M$2.71M
Total assets$35.3M$24M$24.6M$22M$37.8M
Accounts payable$3M$2.27M$3.39M$4.95M$1.3M
Short-term debt$170K$220K$350K$370K$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$11.5M$10.2M$14.7M$32.4M$6.37M
Long-term debt$34.3M$23.4M$1.24M$1.59M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$57.7M$39.6M$37M$1.96M$560K
Capital lease obligations$170K$1.54M$1.59M$1.59M$0.00
Total liabilities$69.2M$49.9M$51.7M$34.3M$6.93M
Common stock$0.00$0.00$0.00$0.00$10K
Retained earnings-$-330.58M-$-279.55M-$-249.5M-$-186.36M-$-136.34M
Accumulated other comprehensive income (loss)$0.00$0.00-$0.00$0.00$0.00
Total equity-$-33.86M-$-25.89M-$-27.07M-$-12.32M$30.9M
Total investments$400K$350K$0.00$250K$0.00
Total debt$34.4M$23.6M$1.59M$1.96M$0.00
Net debt$14M$15.1M-$-10.18M-$-7.45M-$-30.3M
Cash flow statement
20252024202320222021
Net income-$-39.23M-$-30.05M-$-59.36M-$-47.19M-$-28.84M
Depreciation and amortization$630K$740K$680K$400K$460K
Stock-based compensation$9.13M$5.44M$1.4M$370K$110K
Change in working capital$2.07M-$-9.55M$540K$2.3M-$-130K
Accounts receivable-$-1.63M-$-1.72M-$-1.98M-$-200K-$-740K
Inventory$970K-$-1.5M-$-1.07M-$-180K-$-720K
Accounts payable$2.02M-$-4.38M$2.84M$5.25M$3.17M
Net cash provided by operating activities-$-18.01M-$-40.84M-$-50.58M-$-32.31M-$-22.7M
Investments in property, plant and equipment-$-920K-$-340K-$-590K-$-660K-$-1.1M
Acquisitions, net$80K$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-840K-$-340K-$-1.59M-$-1.79M-$-2.26M
Common stock issued$22.9M$15.5M$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$30.8M$37.9M$54.6M$13.5M$50.8M
Net change in cash$11.9M-$-3.25M$2.46M-$-20.64M$25.8M
Cash at end of period$20.8M$8.88M$12.1M$9.66M$30.3M
Operating cash flow-$-18.01M-$-40.84M-$-50.58M-$-32.31M-$-22.7M
Capital expenditure-$-920K-$-340K-$-590K-$-790K-$-1.26M
Free cash flow-$-18.93M-$-41.19M-$-51.17M-$-33.1M-$-23.95M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About TriSalus Life Sciences, Inc.

        TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.

        CEO
        Mary T. Szela
        Employees
        102
        Beta
        0.43

        Explore

        Frequently asked questions

        What is the intrinsic value of TriSalus Life Sciences, Inc. (TLSI)?

        InvestorsCraft does not currently publish an intrinsic value for TLSI. How the IC value is calculated.

        Is TLSI undervalued?

        InvestorsCraft does not publish an undervaluation signal for TLSI at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.